Proteon logo     Print Page | Close Window

SEC Filings

PROTEON THERAPEUTICS INC filed this Form S-1/A on 10/07/2014
Entire Document

Table of Contents

    140,500 shares of common stock reserved for future issuance under 2014 Employee Stock Purchase Plan, which will become effective upon the closing of this offering.

        Unless otherwise indicated, all information in this prospectus reflects or assumes the following:

    the amendment and restatement of our certificate of incorporation and bylaws, which will occur immediately prior to the closing of this offering;
    the conversion of all of our outstanding shares of our preferred stock into 9,103,815 shares of common stock, including the conversion of our Series D convertible preferred stock, assuming the full issuance of incremental shares upon its conversion based on the midpoint of the price range set forth on the cover page of this prospectus, which will occur automatically upon the closing of this offering. See "Capitalization—Series D Convertible Preferred Stock" for applicable conversion price adjustments;
    a one-for-15.87 reverse stock split of our common stock that we effected on October 6, 2014 prior to completion of this offering;
    no exercise of stock options on or after September 30, 2014; and
    no exercise by the underwriters of their option to purchase up to a total of 705,000 additional shares of common stock in this offering.